{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T21:55:29Z","timestamp":1770069329245,"version":"3.49.0"},"reference-count":38,"publisher":"The Endocrine Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2003,5,1]]},"abstract":"<jats:p>Although GH deficiency may underlie the increased cardiovascular risk in adult hypopituitarism, other coexisting hormonal deficiencies and\/or unphysiological hormone replacement may contribute. l-Deamino-8-d-arginine (DDAVP), when administered parenterally, potentiates hemostasis by increasing plasma procoagulant factors. We investigated whether chronic intranasal DDAVP therapy influences clotting factors (plasma fibrinogen, factor VIII, and von Willebrand factor antigen) and endothelial function (flow-mediated dilation of the brachial artery) in 30 GH-treated hypopituitary subjects, including both DDAVP-treated subjects (group A) (mean age, 46 \u00b1 11 yr) and vasopressin-sufficient subjects (group B) (mean age, 47 \u00b1 16 yr). Fifteen healthy controls (group C) (mean age, 48 \u00b1 12 yr) were also studied. All hypopituitary patients were receiving stable GH replacement (median duration, 19 months). Comparing the three groups, concentrations of fibrinogen (mean \u00b1 sd) (A, 3.3 \u00b1 1.0 g\/liter vs. B, 3.5 \u00b1 0.9 vs. C, 2.6 \u00b1 0.8, P &amp;lt; 0.05), factor VIII (A, 130% \u00b1 30% vs. B, 128% \u00b1 30% vs. C, 104% \u00b1 35%, P &amp;lt; 0.05) and von Willebrand factor antigen (A, 124% \u00b1 35% vs. B, 134% \u00b1 45% vs. C, 93% \u00b1 36%, P &amp;lt; 0.05) were higher in hypopituitary subjects, compared with controls. However, there were no differences in clotting factors between groups A and B. Flow-mediated dilation did not differ significantly between the two hypopituitary groups (A, 5.9% \u00b1 2.0% vs. B, 4.7% \u00b1 1.6%) and was similar to that in the control group (C, 5.7% \u00b1 2.1%). In conclusion, although endothelium-dependent vasodilation is intact in GH-treated hypopituitary adults, elevated concentrations of hemostatic markers suggest the persistence of a prothrombotic tendency and endothelial dysfunction. Intranasal DDAVP does not appear to influence this proatherogenic profile in hypopituitary adults with vasopressin deficiency.<\/jats:p>","DOI":"10.1210\/jc.2002-021618","type":"journal-article","created":{"date-parts":[[2003,5,1]],"date-time":"2003-05-01T22:14:18Z","timestamp":1051827258000},"page":"2152-2156","source":"Crossref","is-referenced-by-count":5,"title":["Endothelial Function and Coagulant Factors in Growth Hormone-Treated Hypopituitary Adults Receiving Desmopressin"],"prefix":"10.1210","volume":"88","author":[{"given":"J. C.","family":"Smith","sequence":"first","affiliation":[{"name":"Departments of Medicine (J.C.S., H.A.L., J.L., S.D., L.M.E., M.F.S., J.S.D.), Cardiff CF14 4XN, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. A.","family":"Lane","sequence":"additional","affiliation":[{"name":"Departments of Medicine (J.C.S., H.A.L., J.L., S.D., L.M.E., M.F.S., J.S.D.), Cardiff CF14 4XN, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Lewis","sequence":"additional","affiliation":[{"name":"Departments of Medicine (J.C.S., H.A.L., J.L., S.D., L.M.E., M.F.S., J.S.D.), Cardiff CF14 4XN, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Dann","sequence":"additional","affiliation":[{"name":"Departments of Medicine (J.C.S., H.A.L., J.L., S.D., L.M.E., M.F.S., J.S.D.), Cardiff CF14 4XN, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Goodfellow","sequence":"additional","affiliation":[{"name":"Cardiology (J.G.), Cardiff CF14 4XN, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Collins","sequence":"additional","affiliation":[{"name":"Haematology (P.C.), University Hospital of Wales, Cardiff CF14 4XN, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. M.","family":"Evans","sequence":"additional","affiliation":[{"name":"Departments of Medicine (J.C.S., H.A.L., J.L., S.D., L.M.E., M.F.S., J.S.D.), Cardiff CF14 4XN, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. F.","family":"Scanlon","sequence":"additional","affiliation":[{"name":"Departments of Medicine (J.C.S., H.A.L., J.L., S.D., L.M.E., M.F.S., J.S.D.), Cardiff CF14 4XN, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. S.","family":"Davies","sequence":"additional","affiliation":[{"name":"Departments of Medicine (J.C.S., H.A.L., J.L., S.D., L.M.E., M.F.S., J.S.D.), Cardiff CF14 4XN, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","reference":[{"key":"2020071616565292300_R1","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/0140-6736(90)91812-O","article-title":"Premature mortality due to cardiovascular disease in hypopituitarism.","volume":"336","author":"Rosen","year":"1990","journal-title":"Lancet"},{"key":"2020071616565292300_R2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1046\/j.1365-2265.1997.d01-1749.x","article-title":"Increased cerebrovascular mortality in patients with hypopituitarism.","volume":"46","author":"Bulow","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071616565292300_R3","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0140-6736(00)04006-X","article-title":"Association between premature mortality and hypopituitarism.","volume":"357","author":"Tomlinson","year":"2001","journal-title":"Lancet"},{"key":"2020071616565292300_R4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1210\/er.16.1.63","article-title":"Clinical aspects of growth hormone deficiency.","volume":"16","author":"De Boer","year":"1995","journal-title":"Endocr Rev"},{"key":"2020071616565292300_R5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2265.1999.00682.x","article-title":"Cardiovascular disease and risk factors in adults with hypopituitarism.","volume":"50","author":"Beshyah","year":"1999","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071616565292300_R6","first-page":"1874","article-title":"Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH deficiency.","volume":"86","author":"Colao","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616565292300_R7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1046\/j.1365-2265.2001.01218.x","article-title":"Growth hormone and the heart.","volume":"54","author":"Colao","year":"2001","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071616565292300_R8","first-page":"453","article-title":"Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults.","volume":"84","author":"Pfeifer","year":"1999","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616565292300_R9","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1530\/eje.0.1420254","article-title":"The effect of GH replacement therapy on endothelial function and oxidative stress in adult growth hormone deficiency.","volume":"142","author":"Evans","year":"2000","journal-title":"Eur J Endocrinol"},{"key":"2020071616565292300_R10","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1046\/j.1365-2265.2002.01514.x","article-title":"Effects of GH replacement on endothelial function and large-artery stiffness in GH-deficient adults: a randomized, double-blind, placebo-controlled study.","volume":"56","author":"Smith","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071616565292300_R11","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0950-351X(98)80018-9","article-title":"Growth hormone deficiency and cardiovascular risk.","volume":"12","author":"Hew","year":"1998","journal-title":"Ballieres Clin Endocrinol Metab"},{"key":"2020071616565292300_R12","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3171\/jns.1999.90.2.0251","article-title":"Surgical treatment of craniopharyngiomas: endocrinological results.","volume":"90","author":"Honegger","year":"1999","journal-title":"J Neurosurg"},{"key":"2020071616565292300_R13","first-page":"3897","article-title":"Postoperative prognosis in craniopharyngioma with respect to cardiovascular mortality, survival, and tumor recurrence.","volume":"83","author":"Bulow","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616565292300_R14","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1182\/blood.V90.7.2515","article-title":"Desmopressin (DDAVP) in the treatment of bleeding disorders: the first 20 years.","volume":"90","author":"Mannucci","year":"1997","journal-title":"Blood"},{"key":"2020071616565292300_R15","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1055\/s-0038-1661458","article-title":"Comparative study of intranasal, subcutaneous and intravenous administration of desamino-D-arginine vasopressin (DDAVP).","volume":"55","author":"Kohler","year":"1986","journal-title":"Thromb Haemost"},{"key":"2020071616565292300_R16","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1161\/01.ATV.13.3.393","article-title":"Shear-induced platelet aggregation is potentiated by desmopressin and inhibited by ticlopidine.","volume":"13","author":"Cattaneo","year":"1993","journal-title":"Arterioscler Thromb"},{"key":"2020071616565292300_R17","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1182\/blood.V64.1.229.229","article-title":"DDAVP enhances platelet adherence and platelet aggregate growth on human artery subendothelium.","volume":"64","author":"Sakariassen","year":"1984","journal-title":"Blood"},{"key":"2020071616565292300_R18","first-page":"664","article-title":"Desmopressin and myocardial infarction.","volume":"1","author":"Van Dantzig","year":"1989","journal-title":"Lancet"},{"key":"2020071616565292300_R19","doi-asserted-by":"crossref","first-page":"563","DOI":"10.7326\/0003-4819-114-7-563","article-title":"Nasal spray desmopressin (DDAVP) for mild hemophilia A and von Willebrand disease.","volume":"114","author":"Rose","year":"1991","journal-title":"Ann Intern Med"},{"key":"2020071616565292300_R20","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0301-5629(90)90139-4","article-title":"Assessment of the distensibility of superficial arteries.","volume":"16","author":"Hoeks","year":"1990","journal-title":"Ultrasound Med Biol"},{"key":"2020071616565292300_R21","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1046\/j.1365-2265.1999.00671.x","article-title":"Endothelial dysfunction in hypopituitary adults with growth hormone deficiency.","volume":"50","author":"Evans","year":"1999","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071616565292300_R22","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1161\/01.ATV.18.9.1359","article-title":"Von Willebrand factor: a marker of endothelial damage?","volume":"18","author":"Mannucci","year":"1998","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2020071616565292300_R23","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/hrt.66.5.351","article-title":"Von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death.","volume":"66","author":"Jansson","year":"1991","journal-title":"Br Heart J"},{"key":"2020071616565292300_R24","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1056\/NEJM199503093321003","article-title":"Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group.","volume":"332","author":"Thompson","year":"1995","journal-title":"N Engl J Med"},{"key":"2020071616565292300_R25","doi-asserted-by":"crossref","first-page":"22777","DOI":"10.1016\/S0021-9258(18)54418-5","article-title":"Von Willebrand factor.","volume":"266","author":"Sadler","year":"1991","journal-title":"J Biol Chem"},{"key":"2020071616565292300_R26","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1172\/JCI112736","article-title":"Involvement of large plasma von Willebrand factor (vWF) multimers and unusually large vWF forms derived from endothelial cells in shear stress-induced platelet aggregation.","volume":"78","author":"Moake","year":"1986","journal-title":"J Clin Invest"},{"key":"2020071616565292300_R27","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJM198408233110804","article-title":"Fibrinogen as a risk factor for stroke and myocardial infarction.","volume":"311","author":"Wilhelmsen","year":"1984","journal-title":"N Engl J Med"},{"key":"2020071616565292300_R28","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1161\/01.CIR.100.7.736","article-title":"Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators.","volume":"100","author":"Folsom","year":"1999","journal-title":"Circulation"},{"key":"2020071616565292300_R29","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1210\/jcem-45-4-853","article-title":"Relation between growth hormone levels and von Willebrand factor activity.","volume":"45","author":"Sarji","year":"1977","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616565292300_R30","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/0026-0495(84)90088-X","article-title":"Effects of growth hormone on the factor VIII complex in patients with growth hormone deficiency.","volume":"33","author":"Borkenstein","year":"1984","journal-title":"Metabolism"},{"key":"2020071616565292300_R31","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1161\/01.ATV.14.3.434","article-title":"High fibrinogen and plasminogen activator inhibitor activity in growth hormone-deficient adults.","volume":"14","author":"Johansson","year":"1994","journal-title":"Arterioscler Thromb"},{"key":"2020071616565292300_R32","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1055\/s-0038-1650594","article-title":"Long-term treatment with growth hormone decreases plasminogen activator inhibitor-1 and tissue plasminogen activator in growth hormone-deficient adults.","volume":"76","author":"Johansson","year":"1996","journal-title":"Thromb Haemost"},{"key":"2020071616565292300_R33","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1210\/jcem.86.9.7813","article-title":"Biochemical and biophysical markers of endothelial dysfunction in adults with hypopituitarism and severe GH deficiency.","volume":"86","author":"Elhadd","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616565292300_R34","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1210\/jcem.86.11.7987","article-title":"Acute effect of pegvisomant on cardiovascular risk markers in healthy men: implications for the pathogenesis of atherosclerosis in GH deficiency.","volume":"86","author":"Muller","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071616565292300_R35","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/newbio241217a0","article-title":"Factor 8 on the vascular intima: possible importance in haemostasis and thrombosis.","volume":"241","author":"Bloom","year":"1973","journal-title":"Nat New Biol"},{"key":"2020071616565292300_R36","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1182\/blood.V86.7.2760.2760","article-title":"Desmopressin induces endothelial P-selectin expression and leukocyte rolling in postcapillary venules.","volume":"86","author":"Kanwar","year":"1995","journal-title":"Blood"},{"key":"2020071616565292300_R37","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/0049-3848(88)90328-3","article-title":"Venous thromboembolism and transient thrombocytopenia in a patient with diabetes insipidus treated with desmopressin acetate (DDAVP).","volume":"50","author":"Albert","year":"1988","journal-title":"Thromb Res"},{"key":"2020071616565292300_R38","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1161\/01.CIR.92.11.3212","article-title":"Endothelial control of arterial distensibility is impaired in chronic heart failure.","volume":"92","author":"Ramsey","year":"1995","journal-title":"Circulation"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/88\/5\/2152\/10403457\/jcem2152.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/88\/5\/2152\/10403457\/jcem2152.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,6]],"date-time":"2021-06-06T23:42:37Z","timestamp":1623022957000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/88\/5\/2152\/2845367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5,1]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2003,5,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2002-021618","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,5,1]]}}}